[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"patients-with-hematologic-disorders-after-allogeneic-hematopoietic-stem-cell-transplantation\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:patients-with-hematologic-disorders-after-allogeneic-hematopoietic-stem-cell-transplantation":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":5},"100630108","efficacy-and-safety-of-lusutrombopag-after-allogeneic-hematopoietic-stem-cell-transplantation-100630108",false,"NCT07483385","Efficacy and Safety of Lusutrombopag After Allogeneic Hematopoietic Stem Cell Transplantation","Inclusion Criteria:\n\nParticipants must meet the following criteria:\n\n1. The patient signed an informed consent form and voluntarily participated in the study.\n2. Patients undergoing HLA haploidentical allogeneic hematopoietic stem cell transplantation;\n3. Age ≥18 years, regardless of gender\n4. ECOG score 0-2\n5. Expected survival ≥3 months\n6. No severe impairment of function of major organs\n\nExclusion Criteria:\n\nIf any of the following criteria are met, the participants must be excluded from this research project:\n\n1\\) Patients with known allergy to TPO-RAs; 2) Patients who cannot take oral medication due to gastrointestinal symptoms, altered mental status, etc. during transplantation; 3) Other reasons for exclusion as determined by the investigator.\n\n\\-","ALL","18 Years",{"count":18,"type":19},45,"ESTIMATED","INTERVENTIONAL",[22],"NA","This study is an investigator-initiated prospective, single-center, open-label clinical trial designed to evaluate the clinical efficacy and safety of Lusutrombopag in promoting platelet remodeling after allogeneic hematopoietic stem cell transplantation in patients with hematologic disorders.",[25,26],"Patients With Hematologic Disorders After Allogeneic Hematopoietic Stem Cell Transplantation","Hematologic Disorders","RECRUITING","2026-03-22",{"date":30,"type":31},"2026-03-25","ACTUAL",{"date":33,"type":31},"2026-01-13",{"date":35,"type":19},"2028-01-28",{"name":37,"class":38},"The General Hospital of Western Theater Command","OTHER"]